• CB-839 (Telaglenastat): Optimizing Cancer Metabolism Assays

  2026-06-04

  CB-839 (Telaglenastat) offers researchers a precision tool for dissecting glutamine metabolism and testing glutaminolysis inhibition in preclinical cancer models. This article details streamlined workflows, troubleshooting tips, and the latest protocol enhancements that set CB-839 apart in cancer metabolism research.

• Pexidartinib (PLX3397): Redefining Tumor Macrophage Modulati

  2026-06-04

  Explore how Pexidartinib (PLX3397), a selective CSF1R inhibitor from APExBIO, is reshaping translational oncology by enabling precise experimental control over tumor-associated macrophage populations. This thought-leadership article synthesizes mechanistic insight, strategic workflow guidance, and evidence-based translational perspective, bridging the gap between advanced macrophage biology and actionable cancer research.

• Fucoidan in Oncology: Applied Workflows and Troubleshooting

  2026-06-03

  Fucoidan, a bioactive sulfated α-L-fucan from brown seaweed, enables advanced experimental protocols in cancer research by targeting key tumorigenic pathways and optimizing apoptosis assays. Drawing on cutting-edge studies and hands-on workflow refinements, this article delivers actionable steps and troubleshooting tips for maximizing the impact of APExBIO's high-purity Fucoidan in translational oncology.

• Phosbind Biotin LC: Sequence-Independent Phosphorylation Det

  2026-06-03

  Phosbind Biotin LC enables sensitive, sequence-independent detection of phosphorylated proteins on PVDF membranes in Western Blot workflows, bypassing reliance on phospho-specific antibodies. It is not suited for aqueous-only protocols or for long-term storage of prepared solutions, but is valuable for unbiased protein phosphorylation analysis and downstream applications where phosphorylation state profiling is critical.

• Tetramethylrhodamine Ethyl Ester Perchlorate: Precision in M

  2026-06-02

  Discover how tetramethylrhodamine ethyl ester perchlorate enables precise, mechanism-driven mitochondrial membrane potential and ROS assays. This article explores advanced applications and insights for mitochondrial fluorescence imaging, uniquely integrating recent mechanistic findings with practical assay advice.

• Shufeng Xingbi Therapy Restores Immune Balance and Gut Flora

  2026-06-02

  This study rigorously demonstrates that Shufeng Xingbi Therapy (SFXBT) alleviates allergic rhinitis (AR) symptoms in a rat model by modulating both Th1/Th2 immune balance and intestinal microbiota composition. The findings provide mechanistic insight linking immune regulation with gut microbial shifts, highlighting SFXBT’s translational relevance for immune-microbiota research.

• E-64d: Precision Cysteine Protease Inhibition in Cell Death

  2026-06-01

  E-64d from APExBIO delivers reliable, membrane-permeable inhibition of calpain and cathepsin proteases, empowering researchers to dissect regulated cell death pathways with unprecedented fidelity. Its robust performance in both in vitro and in vivo models makes it the inhibitor of choice for exploring apoptosis, neuroprotection, and cancer cell fate.

• SMYD2 Inhibition with AZ505 Mitigates Cisplatin-Induced Rena

  2026-06-01

  This study demonstrates that pharmacological inhibition of SMYD2, particularly with AZ505, protects against cisplatin-induced renal fibrosis and inflammation in mouse models. The findings highlight SMYD2 as a central epigenetic regulator in chronic kidney disease, with implications for both mechanistic understanding and the development of targeted interventions.

• Ridaforolimus: Applied mTOR Inhibition in Cancer Workflows

  2026-05-31

  Ridaforolimus (Deforolimus, MK-8669) delivers robust, nanomolar-range mTOR inhibition, enabling reproducible antiproliferative and anti-angiogenic assays across diverse cancer cell lines. Optimized for both monotherapy and combination studies, Ridaforolimus is a cornerstone for translational oncology and senescence research.

• Trichostatin A: Unlocking Epigenetic Regulation in Cancer Re

  2026-05-30

  Trichostatin A (TSA) stands out as a benchmark HDAC inhibitor for precision epigenetic modulation in cancer models. Its robust efficacy, reproducibility, and well-characterized protocols empower researchers to dissect chromatin dynamics and drive breakthroughs in oncology.

• Lactate Drives HMGB1 Lactylation and Exosomal Release in Sep

  2026-05-29

  This study uncovers how elevated lactate in sepsis triggers macrophage-mediated HMGB1 lactylation and acetylation, promoting its exosomal release and exacerbating vascular permeability. The findings establish a mechanistic link between metabolic dysregulation and inflammatory signaling, suggesting new intervention points for sepsis therapy.

• 3-Deazaneplanocin (DZNep): Reliable Epigenetic Modulation in

  2026-05-29

  This article addresses real-world laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how 3-Deazaneplanocin (DZNep) (SKU A1905) enables reproducible, high-sensitivity results. Scenario-driven Q&A blocks guide biomedical researchers through protocol optimization, data interpretation, and informed product selection for robust epigenetic research workflows.

• Distinct GluN2A/B Roles in Trigeminal Sensitization During T

  2026-05-28

  This study elucidates how NMDAR subunits GluN2A and GluN2B differentially regulate connexin and pannexin expression in trigeminal ganglia, advancing understanding of orofacial allodynia mechanisms during temporomandibular joint (TMJ) inflammation. The findings identify discrete signaling pathways and cell–cell communication targets of GluN2A/B, pointing to new therapeutic directions for inflammatory pain.

• Cell lysis buffer for WB and IP: Protease/Phosphatase Protec

  2026-05-28

  Cell lysis buffer for WB and IP enables rapid, non-denaturing protein extraction, integrating a robust protease and phosphatase inhibitor cocktail. This preserves protein integrity and native interactions, making it ideal for Western blot and immunoprecipitation workflows across diverse biological samples.

• Scenario-Driven Solutions with Ridaforolimus (Deforolimus, M

  2026-05-27

  This article addresses reproducibility and workflow challenges in cell-based assays by exploring five real-world scenarios where Ridaforolimus (Deforolimus, MK-8669), SKU B1639, delivers validated solutions. Drawing from peer-reviewed literature and the product dossier, it offers practical guidance for biomedical researchers seeking robust mTOR pathway inhibition in cancer and senescence models.

15348 records 5/1024 page Previous Next 12345 下5页 Last page